MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
-4.02%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$796M
AUM Growth
+$796M
(+40%)
Cap. Flow
+$296M
Cap. Flow
% of AUM
37.21%
Top 10 Holdings %
Top 10 Hldgs %
96.21%
Holding
14
New
1
Increased
–
Reduced
4
Closed
1
Top Buys
| 1 |
Cullinan Oncology
CGEM
|
$330M |
Top Sells
| 1 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
$11.9M |
| 2 |
Repare Therapeutics
RPTX
|
$9.78M |
| 3 |
ADC Therapeutics
ADCT
|
$7.85M |
| 4 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$3.74M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
$355K |
Sector Composition
| 1 | Healthcare | 95.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cullinan Oncology
CGEM
$445M
| $330M | 41.43% | +7,913,887 | New | +$330M |
|
|
HARP
2
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $81.6M | 10.25% | 3,898,422 | – | – |
|
3
iTeos Therapeutics
ITOS
| $80.5M | 10.12% | 2,355,557 | – | – |
|
|
TCRR
4
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $74.4M | 9.35% | 3,370,982 | – | – |
|
|
5
Repare Therapeutics
RPTX
$71.7M
| $63.5M | 7.98% | 2,069,749 -318,588 | -13% | -$9.78M |
|
|
ONCR
6
DELISTED
Oncorus, Inc.
ONCR
| $33.1M | 4.16% | 2,377,031 | – | – |
|
|
TPTX
7
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $25.5M | 3.2% | 269,186 -39,500 | -13% | -$3.74M |
|
|
GTHX
8
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $22.3M | 2.8% | 927,794 -496,000 | -35% | -$11.9M |
|
|
EPZM
9
DELISTED
Epizyme, Inc
EPZM
| $20.3M | 2.55% | 2,331,534 | – | – |
|
10
Merus
MRUS
$4.98B
| $14.6M | 1.84% | 700,879 | – | – |
|
11
Y-mAbs Therapeutics
YMAB
$388M
| $10.2M | 1.28% | 337,291 | – | – |
|
|
12
ADC Therapeutics
ADCT
$345M
| $5.32M | 0.67% | 218,027 -321,621 | -60% | -$7.85M |
|
|
AUTL
13
Autolus Therapeutics
AUTL
$399M
| – | – | -39,740 | Closed | -$355K |
|